HIV Archives

gilead hiv aids grant retroviral truvada

News and Trends 23 Feb 2016

How could the HIV Field benefit from Gilead’s new €2M Research Grants?

The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years. Targets are academic institutions and non-profit organization. HIV remains a global health challenge, with around 37 million people infected in the world. The rate of new infections fell in the last decades, but it is […]

February 23, 2016 - 3 minutesmins - By Denise Neves Gameiro

md anderson mologen cancer lung colorectal

News and Trends 21 Jan 2016

Mologen Joins the Rapidly Growing List of EU Partners with the No#1 US Cancer Hospital

MD Anderson (US) and the Berlin Biotech Mologen (Germany) have now partnered on for an Immuno-Oncology program fighting colorectal and small-cell lung carcinoma. The University of Texas MD Anderson Cancer Center is ‘One of the world’s most respected centres‘ devoted exclusively to cancer patient care, research, education and prevention. Having partnered with various European research institutions, medical centres […]

January 21, 2016 - 2 minutesmins - By Dani Bancroft

HIV abivax Alexey Kashpersky abx464 trial antiviral

News and Trends 13 Jan 2016

A Phase II HIV Antiviral from France Has Promising Results

Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy for patients with HIV infection, which could potentially take a corner in an annual $18Bn market. HIV and AIDs have a long-standing history (the quick – yet fascinating story of which can be read here), and since 1983 (when the […]

January 13, 2016 - 3 minutesmins - By Dani Bancroft

News and Trends 3 Nov 2015

€100 Million Investment Round Prepares CureVac For Vaccine Expansion

“The RNA People” at CureVac in Tübingen (Germany) have a new €100M investment into their RNA platform, which has prophylactic purposes for common viruses, pipeline candidates for prostate cancer, lung cancer and research into vaccines for HIV, Tuborculosis and Rabies. Indeed, the financial success surrounding their mRNA work has been startlingly impressive, with the EU […]

November 3, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston – hometown of Moderna – and a research collaboration with the U.S. non-profit International AIDS Vaccine Initiative (IAVI) to develop a mRNA-based HIV treatment. CureVac, today announced the official launch of its U.S. operations in […]

September 10, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 20 Jul 2015

InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine

HIV is definitely under the spotlight today. Just after Theravectys’ announcement about its phase I/II success, InnaVirVax completed a third funding round to accelerate its Phase 2 clinical development. The first-in-class immunotherapy designed to treat HIV infections gained further support by all the historical investors in the company. Since 1987, HIV has mainly been treated with a combination of […]

July 20, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 20 Jul 2015

Theravectys’ HIV Cure on the Road to Success

Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic vaccine using lentivirus could be the first cure available for the 35 million people currently suffering from this worldwide epidemic. Paris-based Theravectys presented detailed results from its phase I/II study at the 2015 Towards an HIV Cure Symposium in Vancouver, Canada. The trial currently enrolled 38 HIV-positive patients […]

July 20, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 5 Jun 2015

Abivax launched an Euronext IPO to build up its anti-viral portfolio

Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech company plans to raise €43.6M. The clinical stage biotech is focused on developing anti-viral compounds and human vaccines. The French biotech want to insufflate the raised cash in its three developing products. Data from the two most advanced ones, ABX203 and ABX464, suggest that […]

June 5, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 22 Feb 2015

Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine

THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its therapeutic vaccine candidate for the treatment of Adult T-cell Leukemia/Lymphoma (ATL/L). ATL/L is a rare malignancy of a certain type of white cells, T-Lymphocytes, caused by the Human T-Cell Lymphotropic Virus type […]

February 22, 2015 - 3 minutesmins - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us